Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efﬁcacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

vispacabtagene regedleucel (CB-010) - Caribou Biosci

Nov 3, 2025